XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ramat Gan, Israel, Oct. 20, 2023 -- XTL Biopharmaceuticals Ltd. , a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of...